Stabilized Antimicrobial Peptides Selective Bacterial Lysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-microbial peptides (AMPs) often face challenges in selectively targeting bacteria without disrupting mammalian membranes, leading to potential cytotoxicity, and there is a need for more effective therapeutic and prophylactic agents that can address microbial infections without harming human cells.
Innovation Solution
Development of structurally-stabilized peptides, including internally cross-linked (ICL) AMPs with specific amino acid sequences and modifications, such as Formula (I), which maintain antimicrobial efficacy while minimizing hemolytic activity, allowing for selective lysis of bacterial cells without harming mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anti-microbial peptides are used to target bacterial membranes, then antimicrobial activity is achieved, but mammalian membrane disruption and cytotoxicity occur
Solution Approach 1:
The peptide structure is modified with local changes including N-terminal acetylation, C-terminal amidation, and specific amino acid substitutions (e.g., lysine to arginine) to create regions with different properties. These local modifications enhance selectivity for bacterial membranes while reducing toxicity to mammalian cells.
Solution Approach 2:
The patent systematically varies key parameters of the peptide including charge density (through amino acid composition), hydrophobicity (through side chain selection), and structural stability (through cyclic constraints). These parameter changes enable optimization of antimicrobial activity while minimizing hemolytic activity.
2Reliability
If peptide concentration is increased to enhance antimicrobial efficacy, then bacterial killing activity improves, but cytotoxicity to human cells increases
Solution Approach 1:
The peptide incorporates structurally dynamic elements including flexible linkers and inducible secondary structures that allow the molecule to adapt its conformation based on the target membrane properties. This dynamic behavior enables effective interaction with bacterial membranes at lower concentrations while maintaining safety.
3Stability of the object's composition
If peptide structure is stabilized to maintain activity, then antimicrobial function is preserved, but selectivity for bacterial over mammalian membranes may be compromised
Solution Approach 1:
The peptide is divided into functional segments including a hydrophobic membrane-interacting region, a cationic charge-rich region for electrostatic attraction to bacterial membranes, and a structurally stabilized core. This segmentation allows each region to contribute specifically to stability while maintaining overall selectivity.
Solution Approach 2:
The peptide combines natural amino acid residues with non-natural amino acid analogs and chemical modifications to create a composite structure. This composite approach provides enhanced structural stability through rigidifying constraints while incorporating selective interaction motifs that distinguish bacterial from mammalian membranes.
Data Source
Figure 1
Figure 2
Figure 3A~3B
AI summary
The present invention provides methods of designing and making structurally stabilized anti-microbial peptides for the prophylaxis and treatment of infection. Methods are also disclosed for designing stabilized anti-microbial peptides that are selectively lytic/cytotoxic to bacteria, allowing for internal use of anti-microbial peptides without mammalian membrane disruption and cytotoxicity.